Trial · NCT01956110
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ongoing Pregnancy Rate | 10-11 weeks after blastocyst transfer | Ongoing pregnancy was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer. |
| Primary | Ongoing Implantation Rate | 10-11 weeks after blastocyst transfer | Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred. |
| Secondary | Vital Pregnancy Rate | 5-6 weeks after blastocyst transfer | Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer. |
| Secondary | Implantation Rate | 5-6 weeks after blastocyst transfer | Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred. |
| Secondary | Proportion of Subjects With Extreme Ovarian Responses, Defined as <4, ≥15 or ≥20 Oocytes Retrieved | Day of oocyte retrieval | |
| Secondary | Proportion of Subjects With Early OHSS (Ovarian Hyperstimulation Syndrome) and/or Preventive Interventions for Early OHSS | ≤9 days after triggering of final follicular maturation | The proportion of subjects with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented. |
| Secondary | Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | End-of-stimulation (up to 20 stimulation days) | Proportion of subjects with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented. |
| Secondary | Number of Oocytes Retrieved | Day of oocyte retrieval | |
| Secondary | Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved | Day of oocyte retrieval | |
| Secondary | Percentage of Metaphase II Oocytes (Oocytes Inseminated Using ICSI [Intracytoplasmic Sperm Injection]) | Prior to insemination | Number of oocytes in metaphase II prior to ICSI insemination is presented. |
| Secondary | Fertilisation Rate | Day 1 after insemination | Fertilisation rate was defined as the number of oocytes with 2 pronuclei divided by the number of oocytes retrieved. |
| Secondary | Number and Quality of Embryos on Day 3 | On day 3 after oocyte retrieval | Number of embryos (total and good-quality) on Day 3 are presented. A good-quality embryo was defined as an embryo with ≥6 blastomeres and fragmentation ≤20% on Day 3. |
| Secondary | Number and Quality of Blastocysts on Day 5 | On day 5 after oocyte retrieval | Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher. |
| Secondary | Total Gonadotropin Dose | End-of-stimulation (up to 20 stimulation days) | The total gonadotropin dose was recorded. |
| Secondary | Number of Stimulation Days | End-of-stimulation (up to 20 stimulation days) | |
| Secondary | Proportion of Subjects With Investigator-requested Gonadotropin Dose Adjustments | End-of-stimulation (up to 20 stimulation days) | |
| Secondary | Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period | End-of-stimulation (up to 20 stimulation days) | Subjects self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessments performed is presented. |
| Secondary | Abdominal Discomfort Related to Controlled Ovarian Stimulation as Assessed by a Visual Analogue Scale (VAS) | End-of-stimulation and day of blastocyst transfer | The subject self-assessed abdominal discomfort related to controlled ovarian stimulation using a VAS going from 0 mm (no abdominal discomfort) to 100 mm (worst imaginable abdominal discomfort). |
| Secondary | Changes in Body Weight | End-of-stimulation and day of blastocyst transfer | Change in body weight from baseline to end-of-stimulation and from baseline to day of blastocyst transfer. |
| Secondary | Changes in Maximum Abdominal Circumference | End-of-stimulation and day of blastocyst transfer | Change in maximum abdominal circumference from baseline to end-of-stimulation and from baseline to day of blastocyst transfer. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01956110/registered